| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $1,785,489 | 5 | 56 |
Sells | $128,614 | 4 | 44 |
| Stansky Michael P | director | 1 | $1.48M | 0 | $0 | $1.48M |
| Szela Mary T | CEO and President | 1 | $124,997 | 0 | $0 | $124,997 |
| Valle William | director | 1 | $124,997 | 0 | $0 | $124,997 |
| Gordon Gary B. | director | 1 | $40,000 | 0 | $0 | $40,000 |
| Patience David | Chief Financial Officer | 1 | $14,994 | 0 | $0 | $14,994 |
| Cox Bryan F. | Chief of Research | 0 | $0 | 1 | $24,678 | $-24,678 |
| Devlin Jodi | Chief of Clinical Operations | 0 | $0 | 1 | $24,678 | $-24,678 |
| Marshak Richard | Chief Commercial Officer | 0 | $0 | 1 | $34,172 | $-34,172 |
| Stevens Jennifer | Chief Regulatory Officer | 0 | $0 | 1 | $45,087 | $-45,087 |
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Over the last 12 months, insiders at TriSalus Life Sciences, Inc. have bought $1.79M and sold $128,614 worth of TriSalus Life Sciences, Inc. stock.
On average, over the past 5 years, insiders at TriSalus Life Sciences, Inc. have bought $1.31M and sold $120,379 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Stansky Michael P (director) — $1.48M. Szela Mary T (CEO and President) — $124,997. Valle William (director) — $124,997.
The last purchase of 361,098 shares for transaction amount of $1.48M was made by Stansky Michael P (director) on 2026‑02‑23.
| 2026-02-23 | Stansky Michael P | director | 361,098 0.898% | $4.10 | $1.48M | +5.21% | ||
| 2026-02-23 | Szela Mary T | CEO and President | 30,487 0.0758% | $4.10 | $124,997 | +5.21% | ||
| 2026-02-23 | Patience David | Chief Financial Officer | 3,657 0.0091% | $4.10 | $14,994 | +5.21% | ||
| 2026-02-23 | Valle William | director | 30,487 0.0758% | $4.10 | $124,997 | +5.21% | ||
| 2026-02-23 | Gordon Gary B. | director | 9,756 0.0243% | $4.10 | $40,000 | +5.21% | ||
| 2025-05-19 | Sale | Cox Bryan F. | Chief of Research | 4,764 0.0126% | $5.18 | $24,678 | -3.28% | |
| 2025-05-19 | Sale | Stevens Jennifer | Chief Regulatory Officer | 8,704 0.023% | $5.18 | $45,087 | -3.28% | |
| 2025-05-19 | Sale | Marshak Richard | Chief Commercial Officer | 6,597 0.0174% | $5.18 | $34,172 | -3.28% | |
| 2025-05-19 | Sale | Devlin Jodi | Chief of Clinical Operations | 4,764 0.0126% | $5.18 | $24,678 | -3.28% | |
| 2025-02-05 | Young James Emmett | Chief Financial Officer | 6,000 0.0208% | $5.65 | $33,900 | -3.00% | ||
| 2025-01-30 | Szela Mary T | CEO AND PRESIDENT | 5,010 0.0177% | $5.28 | $26,453 | +1.57% | ||
| 2025-01-29 | Szela Mary T | CEO AND PRESIDENT | 5,030 0.0167% | $5.03 | $25,301 | +6.13% | ||
| 2025-01-28 | Szela Mary T | CEO AND PRESIDENT | 4,716 0.0157% | $5.12 | $24,146 | +4.43% | ||
| 2025-01-28 | Murphy Sean | Chief Manuf, Strategy&Bus Dev. | 15,000 0.0504% | $5.17 | $77,550 | +4.43% | ||
| 2025-01-27 | Szela Mary T | CEO AND PRESIDENT | 4,826 0.0159% | $5.42 | $26,157 | -2.08% | ||
| 2025-01-27 | Murphy Sean | Chief Manuf, Strategy&Bus Dev. | 15,000 0.0483% | $5.31 | $79,650 | -2.08% | ||
| 2025-01-27 | Young James Emmett | Chief Financial Officer | 24,000 0.0786% | $5.40 | $129,600 | -2.08% | ||
| 2024-12-17 | Frankenius Equity AB | 10 percent owner | 62,972 0.2076% | $3.97 | $249,999 | +34.12% | ||
| 2024-12-10 | Sale | Desai Arjun JJ | director | 30,000 0.0984% | $3.69 | $110,700 | +32.47% | |
| 2024-11-22 | Wahlstrom Mats | 5,000 0.0164% | $4.55 | $22,750 | +10.82% |
| Stansky Michael P | director | 787132 2.3825% | $3.94M | 1 | 0 | |
| Szela Mary T | CEO and President | 773289 2.3406% | $3.87M | 8 | 0 | +1.93% |
| Patience David | Chief Financial Officer | 268657 0.8132% | $1.34M | 1 | 0 | |
| Cox Bryan F. | Chief of Research | 119415 0.3614% | $597,075.00 | 0 | 2 | |
| Stevens Jennifer | Chief Regulatory Officer | 77640 0.235% | $388,200.00 | 0 | 1 | |
| Marshak Richard | Chief Commercial Officer | 69101 0.2092% | $345,505.00 | 0 | 1 | |
| Devlin Jodi | Chief of Clinical Operations | 52764 0.1597% | $263,820.00 | 0 | 1 | |
| Valle William | director | 30487 0.0923% | $152,435.00 | 1 | 0 | |
| Gordon Gary B. | director | 9756 0.0295% | $48,780.00 | 1 | 0 | |
| Frankenius Equity AB | 10 percent owner | 6230748 18.8595% | $31.15M | 1 | 0 | +34.12% |
| Martin George Kelly | director | 247176 0.7482% | $1.24M | 0 | 1 | |
| Desai Arjun JJ | director | 247127 0.748% | $1.24M | 0 | 1 | |
| Murphy Sean | Chief Manuf, Strategy&Bus Dev. | 197732 0.5985% | $988,660.00 | 2 | 0 | +1.18% |
| Young James Emmett | Chief Financial Officer | 30000 0.0908% | $150,000.00 | 2 | 0 | <0.0001% |
| Wahlstrom Mats | 15727 0.0476% | $78,635.00 | 3 | 0 | +15.83% |
$1,105,104 | 34 | -11.40% | $265.95M | |
$58,432,429 | 19 | 7.16% | $391.68M | |
$5,183,021 | 19 | -4.75% | $69.71M | |
TriSalus Life Sciences, Inc. (TLSI) | $783,570 | 13 | 7.19% | $165.19M |
$165,149 | 7 | -44.78% | $9.13M | |
$14,564 | 7 | 27.01% | $8.23M | |
$12,684,208 | 6 | 17.63% | $14.56M | |
$24,971 | 6 | -37.72% | $44.19M | |
$330,888 | 5 | 7.30% | $182,688.00 | |
$21,637 | 4 | -55.86% | $2.3M | |
$7,003,990 | 3 | -17.01% | $915.83M | |
$13,650 | 1 | -48.97% | $6.65M | |
$19,977 | 1 | 10.97% | $352.17M |
| Increased Positions | 40 | +70.18% | 2M | +23.7% |
| Decreased Positions | 22 | -38.6% | 478,418 | -4.93% |
| New Positions | 14 | New | 337,360 | New |
| Sold Out Positions | 9 | Sold Out | 123,062 | Sold Out |
| Total Postitions | 75 | +31.58% | 12M | +18.77% |
| Nantahala Capital Management, Llc | $12,445.00 | 4.08% | 2.04M | +40,245 | +2.01% | 2025-09-30 |
| Awm Investment Company, Inc. | $7,625.00 | 2.5% | 1.25M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $7,073.00 | 2.32% | 1.16M | +345,186 | +42.39% | 2025-09-30 |
| Gilder Gagnon Howe & Co Llc | $6,387.00 | 2.09% | 1.05M | -45,916 | -4.2% | 2025-09-30 |
| Blackrock, Inc. | $4,806.00 | 1.58% | 787,864 | +166,175 | +26.73% | 2025-09-30 |
| Wealthcare Advisory Partners Llc | $3,927.00 | 1.29% | 643,740 | 0 | 0% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $3,401.00 | 1.12% | 557,500 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $3,382.00 | 1.11% | 554,455 | +99,404 | +21.84% | 2025-09-30 |
| State Street Corp | $1,175.00 | 0.39% | 192,633 | +77,036 | +66.64% | 2025-09-30 |
| Bank Of America Corp /De/ | $1,154.00 | 0.38% | 189,180 | +274 | +0.14% | 2025-09-30 |